Serrapeptase is a protein enzyme isolated from the non-pathogenic enterobacteria Serratia E15 found in silkworms. Once the silkworm has completed its transformation into a moth, it uses this substance to “melt” a hole in its cocoon, thus that it can escape. This enzyme is absorbed through the intestines and transported directly into the bloodstream.
Serrapeptase Benefits and Medical Researches
Serrapeptase enzyme, particularly in Asia and Europe it is clinically used for anti-inflammatory problems such as arthritis, atherosclerosis, fibrocystic breast disease and carpal tunnel syndrome.
Serratiopeptidase is able to dissolve the fibrin and other dead or damaged tissue without harming living tissue. This could enable the dissolution of atherosclerotic plaques without causing any harm to the inside of the arteries. Hans Nieper, German doctor, has reported important improvements from serrapeptase therapy in the circulation of a number of patients with previously compressed arteries. Especially, advises the use of this enzyme to treat blocked carotid arteries when classic surgery is too risky. Because the enzyme digests non-living tissue and leaves live tissue alone, it may be efficacious in removing the deposits of fatty substances, cellular waste products, cholesterol, calcium and fibrin on the inside of the arteries. The fibrinolytic activity of serrapeptase may also be able to help with thickened blood, increased risk of stroke, and phlebitis.
In his researches, Dr. Nieper proved that serratiopeptidase was capability of dissolving and digesting the substances that cause plaque formation on the arterial walls, such as cholesterol, calcium, cellular wastes, various fats, and fibrin, a clotting agent. Excessive plaque results in partial or complete blockage of blood flow through an artery, resulting in arteriosclerosis which could cause a heart attack or stroke. Dr. Nieper explained that serratiopeptidase digests non-living tissue, blood clots, cysts, arterial plaque and inflammation in all forms. It protects against strokes and has been found to be more effectual and fast than EDTA chelation therapies in removing arterial plaque. Serrapeptase acts to safely and effectively reverse chronic inflammation. In recent years, a growing number of sresearchers have come to realize that one of the primary causes for the deposits of deleterious, plaque-forming substances inside arterial walls is chronic, low-grade inflammation.
Serratiopeptidase is a strong therapy for pain and inflammation. Various researches confirm its anti-inflammatory effects, and it has been used for this reason in the reduction of chronic sinusitis and other chronic or acute inflammatory conditions. Serratiopeptidase anti-inflammatory effects are similar to those of the ibuprofen, salicylates and non-steroidal anti-inflammatories. Unlike NSAID pain drugs, serrapeptase does not cause risky internal bleeding nor is it addictive like other pain drugs. In a study 2008; compared serrapeptase and its anti-inflammatory effect with aspirin and two human pancreatic proteolytic enzymes (chymotrypsin and trypsin). Though all groups were effective at reducing inflammation, serrapeptase was the most effective.
In various studies serratiopeptidase has significantly reduced the elasticity and viscosity of nasal mucus offering great help to people with chronic sinus problems. Serrapeptase reduces the thickness and viscosity of the mucus and improves the elimination of it through bronchopulmonary secretions. Patients treated with serrapeptase for sinusitis and laryngitis experienced a significant decreased in severity of pain, rapid improvement of symptoms after 3-4 days, as well as decreased in nasal stuffiness, infected secretions, and fever. In a study conducted in Italy, gave serratiopeptidase to 193 participants suffering from acute or chronic ear, nose or throat problems over a period of 3 to 4 days. The scientists rated therapy as excellent or good for 97% of participants taking serratiopeptidase compared with just 21% in the placebo group. A study in Japan investigated the efficacy of serratiopeptidase on sputum properties and symptoms in individuals with chronic airway diseases. After four weeks of serratiopeptidase therapy, sputum output, viscosity and sputum neutrophil count decreased significantly. A study reported in the March 2008 edition of Journal of Oral and Maxillofacial Surgery demonstrated that Serratiopeptidase supplement reduced pain and inflammation following dental surgery.
Carpal Tunnel Syndrome (CTS) is an inflammatory disease of the hand and wrist that is characterized by intense, longlasting pain, inflammation and disability. CTS is usually the result of a combination of factors that increase pressure on the median nerve and tendons in the carpal tunnel, rather than a problem with the nerve itself. Symptoms mostly start gradually, with frequent burning, tingling, or itching numbness in the palm of the hand and the fingers, particularly the thumb and the index and middle fingers. Scientists in India conducted a study to assess the response of serratiopeptidase in people with carpal tunnel syndrome. 20 patients with carpal tunnel syndrome were evaluated clinically after six weeks taking serratiopeptidase. 65 % demonstrated significant clinical development, which was supported by improvement in electrophysiological parameters. While surgery had been considered the first therapy, new researches reveal that the use of serratiopeptidase in conjunction with bromelain and Vitamins B2 and B6 is also useful.
Serratiopeptidase has proven invaluable in accelerating the healing process for leg ulcers, torn ligaments, sprained muscles, and other traumatic injuries, edema as well as post-operative inflammation. A study was conducted on the effect of serratiopeptidase on post-operative pain of the ankle and swelling. In the serratiopeptidase group, the swelling decreased by 50 percent on the third post-operative day, while in the control groups no reduction in swelling occurred. Another double-blind study, reported in the “Pharmatherapeutica“, found that serratiopeptidase reduced swelling in patients who underwent surgery to treat empyema. A cyst or a benign fibrocystic lump that moves freely within the breast tissue characterizes fibrocystic breast disease, a condition that affects millions of women. In a double-blind study, serratiopeptidase was found to decrease breast pain, breast swelling and induration in 85.7 percent of the patients taking the supplement. Experts concluded that serratiopeptidase is a influential and safe remedy for the therapy of breast engorgement.
The enzyme activity is measured in units and are based on the ratio of 10 mg of serratiopeptidase equaling 20,000 units of activity. According to Dr. Nieper, just 3 three 5 mg tablets of serrapeptase daily for twelve to eighteen months are sufficient to remove fibrous blockages from constricted coronary arteries, as confirmed in many of his patients by ultrasound examination. For pain, start with 10 mg daily and work up to 20 mg if necessary. Serrapeptase capsules and tablets are enteric coated and are taken on an empty stomach to ensure that they are activated in the small intestine, rather than in the stomach. Non-enteric coated capsules or tablets are rapidly destroyed by the stomach acid.